Understanding Your Lymphoma Diagnosis: Making Sense of Over 100 Different Types Lymphoma is a cancer that affects lymphocytes, a type of white blood cell that helps protect the body from infection. While lymphoma is the most common type of blood…
Updates from the 2024 American Society of Hematology Annual Meeting The Lymphoma Research Foundation returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with 264 Foundation-affiliated scientists, including past and present members of the Foundation’s world-leading Scientific…
Finding Hope and Healing Through Music For Roger O’Donnell, longtime keyboardist of the legendary alternative rock band The Cure, music has always been about forging his own path. “Our band has made a successful career out of turning left when…
Helping Patients With Lymphoma Live Not Only Longer, But Better As the daughter of a Malaysian diplomat and an international environmental lawyer, Gita Thanarajasingam, MD, a hematologist at Mayo Clinic in Rochester, Minnesota, had a truly global upbringing. From Kuala…
Where Are They Now? Helen Ma, MD, MS Helen Ma, MD, MS, is the assistant professor in the Division of Hematology and Oncology in the Department of Medicine at the University of California Irvine. When did you become interested in…
The Key to Hope Lies in Research When Joanne Downing first noticed a lump in her neck while playing golf one sunny Florida day in 2001, her first inclination was to dismiss it. However, her friend and golf partner —…
ASH 2024: Inequitable Patterns in Fertility Counseling Reported by Patients with NHL Late effects from non-Hodgkin lymphoma (NHL) treatment can lead to decreased fertility, which may be of particular concern for adolescents and young adults. Utilization of fertility counseling is…
ASH 2024: Real-World Clinical Outcomes With Novel Therapies in Relapsed/Refractory MCL Vary Based on Race and Ethnicity The treatment for relapsed/refractory mantle cell lymphoma (MCL) has been revolutionized by the emergence of novel therapies such as Bruton’s tyrosine kinase inhibitors…
ASH 2024: First-Line Treatment Choice Impacts Risk for Other Malignancies in CLL and SLL Patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) have previously been shown to be at increased risk for developing other malignancies relatively to…
ASH 2024: Interim Results from the AMPLIFY Study Show Durable Responses with Acalabrutinib Plus Venetoclax in Treatment-Naïve CLL Use of fixed-duration Bruton tyrosine kinase inhibitor (BTKi) therapy in treatment-naïve chronic lymphocytic leukemia (CLL) is complicated by the limited efficacy and…